Inhibrx Biosciences (INBX) Current Assets (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Current Assets data on file, last reported at $132.8 million in Q4 2025.

• Current Assets for Q4 2025 came in at $132.8 million, down 17.19% year-over-year; the trailing twelve-month figure through Dec 2025 was $132.8 million (down 17.19% YoY), and the FY2025 annual result was $132.8 million, down 17.19% from the prior year.
• Current Assets declined to $132.8 million in Q4 2025 per INBX's latest filing, from $161.4 million in the prior quarter.
• Over five years, Current Assets peaked at $295.4 million in Q4 2023 and troughed at $132.8 million in Q4 2025.
• A 3-year average of $202.1 million and a median of $200.7 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2025: Current Assets slumped 45.69% in 2024, then fell 17.19% in 2025.
• A 3-year view of Current Assets shows it stood at $295.4 million in 2023, then tumbled by 45.69% to $160.4 million in 2024, then slipped by 17.19% to $132.8 million in 2025.
• Business Quant data shows INBX's Current Assets at $132.8 million in Q4 2025, $161.4 million in Q3 2025, and $194.0 million in Q2 2025.